US Patent

US8247416 — Phthalazinone derivative

Composition of Matter · Assigned to Kudos Pharmaceuticals Ltd · Expires 2028-09-24 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the crystalline Form A of the phthalazinone derivative 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one.

USPTO Abstract

4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.

Drugs covered by this patent

Patent Metadata

Patent number
US8247416
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-09-24
Drug substance claim
Yes
Drug product claim
No
Assignee
Kudos Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.